Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
- Resource Type
- Article
- Source
- Targeted Oncology; Jan2024, Vol. 19 Issue 1, p59-69, 11p
- Subject
- Language
- ISSN
- 17762596